After that 18-month trial, patients could lose access to Medicare coverage for GLP-1s used for weight loss unless the Centers for Medicare & Medicaid Services issues an extension or Congress changes the law, according to Cubanski
" More research is needed into why and how these taste change vary across individuals as GLP-1s become an increasingly mainstream option for weight loss, Doty and other experts say especially as use among Americans has more than doubled in the past year
The useful question is not whether retatrutide sounds intense
These statements have not been evaluated by the Food and Drug Administration
The market in North America is expected to increase due to its sophisticated manufacturing capabilities, robust pharmaceutical demand, and concentration of top-tier CDMOs that can support large-scale clinical and commercial peptide production
If further glucose lowering is needed, the dose may increase to 14 mg after at least 30 days on 7 mg